- Home
- FDS vs RNA Comparison
FDS vs RNA Comparison
Compare FDS & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDS | RNA |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | 6258 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.9B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FDS | RNA |
|---|---|---|
| Price | $220.34 | $15.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $300.10 | $69.26 |
| AVG Volume (30 Days) | 1.3M | ★ 3.0M |
| Earning Date | 03-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | ★ 11.79 | N/A |
| EPS | ★ 4.06 | N/A |
| Revenue | ★ $1,435,351,000.00 | $18,755,000.00 |
| Revenue This Year | $6.56 | $88.12 |
| Revenue Next Year | $5.30 | $18.11 |
| P/E Ratio | $53.43 | ★ N/A |
| Revenue Growth | 6.31 | ★ 72.11 |
| 52 Week Low | $185.00 | $13.06 |
| 52 Week High | $473.33 | $73.06 |
Technical Indicators
Market Signals| Indicator | FDS | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 1.42 |
| Support Level | $185.00 | N/A |
| Resistance Level | $301.18 | $72.43 |
| Average True Range (ATR) | 11.02 | 0.49 |
| MACD | 4.95 | -5.86 |
| Stochastic Oscillator | 98.69 | 3.30 |
Price Performance
Historical ComparisonAbout FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.